 |
Historically, G2 has been the second most common cause of
rotavirus gastroenteritis in the United States, after G1.1,a
aThe distribution of serotypes identified in 2005-2007 (n=817) was: G1 P[8], 65.1%;
G2 P[4], 15.9%; G3 P[8], 1.5%; G4 P[8], 0.1%; G9 P[8], 1.7%; other, 15.6%.2
Select safety information
- RotaTeq should not be administered
to infants with a demonstrated history of hypersensitivity
to the vaccine or any component
of the vaccine.
- No safety or efficacy data are available
for the administration of RotaTeq to infants who are potentially
immunocompromised
or to infants with a history
of
gastrointestinal disorders.
- Caution is advised when considering whether
to administer RotaTeq to individuals with immunodeficient
contacts.
- In clinical trials, the most common adverse events
included diarrhea, vomiting, irritability, otitis media,
nasopharyngitis, and bronchospasm.
- In post-marketing experience,
intussusception (including death) and Kawasaki disease
have been reported in infants who
have received RotaTeq.
- RotaTeq may not protect all vaccine
recipients against rotavirus.
Before administering RotaTeq, please read the Prescribing
Information
and Patient
Product Information.
RotaTeq is a registered trademark of Merck & Co.,
Inc.
|
